Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss

The U.S. Food and Drug Administration is reviewing reports of nonarteritic anterior ischemic optic neuropathy, a form of vision loss, among patients taking GLP-1 medications including Ozempic and Zepbound, according to statements from the agency. NAION involves reduced blood flow to the optic nerve and can result in sudden vision loss. Multiple medical studies have documented an elevated risk of NAION in people taking GLP-1 drugs, which are primarily used to treat type 2 diabetes and obesity.

• MarketWatch — Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss

Next story